Ignite Creation Date:
2025-12-24 @ 4:08 PM
Ignite Modification Date:
2026-01-24 @ 3:44 AM
Study NCT ID:
NCT04049266
Status:
TERMINATED
Last Update Posted:
2024-07-18
First Post:
2019-08-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Sponsor:
Kodiak Sciences Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Wet Macular Degeneration | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | AMD | View |
| None | Wet AMD | View |
| None | choroidal neovascularization secondary to age-related macular degeneration | View |
| None | KSI-301 | View |
| None | Aflibercept | View |
| None | Vascular endothelial growth factor | View |
| None | VEGF | View |
| None | Anti-VEGF | View |
| None | Antibody biopolymer conjugate | View |
| None | Macular Degeneration | View |
| None | Wet Macular Degeneration | View |
| None | Retinal Degeneration | View |
| None | Retinal Diseases | View |
| None | Eye Diseases | View |
| None | Vision Disorders | View |
| None | Vision, low | View |
| None | Kodiak | View |